Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16197721 | 0.90 | CTSK (0.39) | CTSKHDAC6HDAC1HDAC2GPR88 | |
| SCHEMBL2917271 | 0.79 | HDAC6 (0.39) | CTSKHDAC6HDAC1HDAC2GPR88 | |
| SCHEMBL16941095 | 0.79 | CTSK (0.39) | CTSKHDAC6HDAC1HDAC2GPR88 | |
| SCHEMBL21784362 | 0.79 | HDAC6 (0.36) | CTSKHDAC6HDAC1HDAC2NFKB1 | |
| SCHEMBL21574215 | 0.78 | CTSK (0.40) | CTSKHDAC6HDAC1HDAC2GPR88 | |
| SCHEMBL21444884 | 0.78 | CA14 (0.42) | CTSKHDAC6HDAC1HDAC2GPR88 | |
| SCHEMBL15866143 | 0.78 | CTSK (0.40) | CTSKHDAC6HDAC1HDAC2GPR88 | |
| SCHEMBL10260946 | 0.78 | HDAC6 (0.40) | CTSKHDAC6HDAC1HDAC2PDK2 | |
| SCHEMBL21918067 | 0.78 | CHRNB2 (0.36) | CTSKHDAC6HDAC1HDAC2GPR88 | |
| SCHEMBL3711368 | 0.77 | CTSK (0.38) | CTSKHDAC6HDAC1HDAC2GPR88 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11918656-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2024-03-05 | — | — | US | disclosed |
| US-20230002316-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2023-01-05 | — | — | US | disclosed |
| US-20230002316-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2023-01-05 | — | — | US | disclosed |
| EP-3607996-B1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2023-01-04 | — | — | EP | disclosed |
| EP-3607996-B1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2023-01-04 | — | — | EP | disclosed |
| US-11517625-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2022-12-06 | — | — | US | disclosed |
| US-11517625-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2022-12-06 | — | — | US | disclosed |
| US-20220105195-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2022-04-07 | — | — | US | disclosed |
| EP-3388427-B1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PF MEDICAMENT (FR) | 2022-01-19 | — | — | EP | disclosed |
| US-11219693-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2022-01-11 | — | — | US | disclosed |
| US-10314921-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2019-06-11 | — | — | US | disclosed |
| US-20180222858-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2018-08-09 | — | — | US | disclosed |
| US-20180222858-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2018-08-09 | — | — | US | disclosed |
| US-20170043032-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-02-16 | — | — | US | disclosed |
| US-20170043032-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-02-16 | — | — | US | disclosed |
| US-20160068566-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2016-03-10 | — | — | US | disclosed |
| US-20160068566-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2016-03-10 | — | — | US | disclosed |
| US-20160068566-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2016-03-10 | — | — | US | disclosed |
| WO-2015162293-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2015-10-29 | — | — | WO | disclosed |
| WO-2014174060-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2014-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170043032-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | KRTCAP2, DDOST, DAD1 | CTSK 1720/4885HDAC6 121/4885HDAC1 1485/4885 |
| US-20180222858-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | NR1H4, HCAR3, VDR | CTSK 3323/4885HDAC6 195/4885HDAC1 227/4885 |
| US-11517625-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DDOST, DAD1, KRTCAP2 | CTSK 1361/4885HDAC6 135/4885HDAC1 1966/4885 |
| US-20160068566-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | NR1H4, HCAR3, VDR | CTSK 3390/4885HDAC6 196/4885HDAC1 238/4885 |
| US-20230002316-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | NR1H4, HCAR3, VDR | CTSK 3323/4885HDAC6 195/4885HDAC1 227/4885 |
| US-11219693-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DAD1, DDOST, KRTCAP2 | CTSK 1806/4885HDAC6 180/4885HDAC1 1969/4885 |
| US-11918656-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DDOST, DAD1, KRTCAP2 | CTSK 1361/4885HDAC6 135/4885HDAC1 1966/4885 |
| US-20220105195-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | KRTCAP2, DDOST, DAD1 | CTSK 1720/4885HDAC6 121/4885HDAC1 1485/4885 |
| US-10314921-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | KRTCAP2, DDOST, DAD1 | CTSK 1720/4885HDAC6 121/4885HDAC1 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.